Charles A. Henriques NeurogesX Inc.15% owner. QUTENZA developer - Non-Opioid Pain Therapies For Unmet Needs In Neuropathic Pain Neuropathic Pain Investor Sacred Heart University Fairfield CT BS/BA Business Administration San Francisco Bay Area 500+ 500+ connections Charles A. Henriques increased stake in NeurogesX, Inc. Filed SC 13G/A form with U.S. Securities and Exchange Commission on February 13, 2017. Amount beneficially owned: 4,966,649 NGSX shares. CUSIP# 641252101.
Form 13G is used when the filer owns between 5% and 20% of the company and plans to hold it only as a passive investor. If the filler intend to exert control and if the stake’s size exceeds 20%, then a 13D must be filed. Therefore, activist investors and practices such as: hostile takeovers, company breakups, and other “change of control” events, are not permitted by 13G filers.
NeurogesX Inc. (NeurogesX), is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, Pain Management Therapies to address unmet medical needs. Qutenza the Company’s first commercial product, has FDA approval, available in USA by Acorda Therapeutics Inc. EU approval in 2009 and available at Astellas Pharma in all 28 European countries.
Qutenza is a dermal delivery system designed to topically administer capsaicin to treat certain neuropathic pain conditions. Approved by the FDA for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In September 2015, the European Commission approved a label extension for Qutenza to include diabetic patients with neuropathic pain, adding more value to product.
QUTENZA has a Patented Synthetic Capsaicin that works faster and better than Lyrica according to a study published in the European Journal of Pain, funded by Astellas Pharma Europe Ltd,
Lyrica is Pfizer’s top selling drug with annual worldwide sales of over $5 billion.
Grunenthal News 12 -12 -17 Acquiring Commercialization Rights for Qutenza® From Astellas.
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany
Why is this at a 52 Week low ?
ALPMY bought out OCATA two years ago. Anyone know what happened to the AMD trials that was in progress at that time? I have not seen any reports.
This should double within two yrs.
Thanks for the tip, I did some research and found more information about $ALPMF on http://yugestocks.com/?s=ALPMF Day trading making money. Broder's law: anyone who wants the presidency so much that he'll spend two years organizing the campaigning for it
Yuge Stocks: Trading Stocks and Making Money
Stock alerts from the Yuge Stocks. Stock trading, making money and always looking for the next big money maker.
Stock alerts from the Monsta Stocks. Stock trading, making money and always looking for the next big money maker.
Ocata shareholders: Aren't you glad you bought into this?
Received an alert this am about $ALPMY from http://monstatrader.com/?s=ALPMY, you may want to take a look. Trading stocks investing. Eugene o'neull on data-bases: a checkpoint runs a long day's journal into night.
MonstaTrader: OTC, NYSE, NASDAQ Stock Alerts for all Traders
Stock alerts, stock trading, making money, sharing knowledge and always looking for the next big money maker.